Haselmeier, a developer and manufacturer of innovative self-injection devices headquartered in St. Gallen, Switzerland, has announced the signing of an exclusive agreement with the Stevanato Group (Piombino Dese, Italy) to license Axis-D pen-injector technology and intellectual property for the development, manufacture and supply of the injector for diabetes care.
The Axis-D pen-injector was designed and developed by Haselmeier together with its partners. A version of the pen-injector is currently marketed by a major pharmaceutical company and is approved for use by the European Medical Agency (EMA) and FDA, among other regulatory bodies.
The Stevanato Group plans to utilize this technology and IP to provide a new pen injector to support the needs of diabetes patients. Once the design for the device has been finalized, it will be produced at one of Stevanato Group’s manufacturing facilities with extensive tooling and molding expertise, said the press release. Sub-assembly and final assembly equipment will be provided by Stevanato Group’s operations in Denmark.
The Stevanato Group is the world’s largest privately owned designer and producer of glass parenteral packaging for the pharmaceutical industry. Its member companies include Balda, which is dedicated to manufacturing diagnostic consumables, delivery devices and medical components. Balda (Bad Oeynhausen, Germany) offers advanced injection molding capabilities and plastics expertise at facilities in Germany, Romania and the United States. Stevanato acquired Balda in 2016.
“We are pleased and proud to have Stevanato Group as our strategic partner for Axis-D in diabetes,” said Frédéric Gabriel, Chief Innovation Officer at Haselmeier, in a prepared statement. “Stevanato Group has demonstrated in past years a consistent development strategy coupled with unique integrated capabilities and is able to leverage Haselmeier’s pen injection platform to bring it to the next level,” added Gabriel.
“Stevanato Group always welcomes strategic agreements with key players in the market to broaden its global capabilities,” commented Paolo Patri, Chief Technology Officer at Stevanato Group. “With this agreement, we continue to expand our portfolio of devices for patients suffering from diabetes. This complements ongoing work on our award-winning 1-ml cartridge-based wearable device, which will give our biopharmaceutical partners the opportunity to provide patients with both standard and alternative treatment solutions. "